对《ASCO指南中有关PARP抑制剂治疗卵巢癌的临床推荐意见》的点评

根据ASCO指南,解读多聚（ADP-核糖）聚合酶抑制剂（PARPi）在上皮性卵巢癌、输卵管癌或原发性腹膜癌中的应用。ASCO指南建议基于既往已发表文献的循证证据、美国食品药品监督管理局的相关审批文件以及相关证据缺乏时的专家共识,最终纳入17项符合标准的临床研究。本指南适用于PARPis初治患者,对PARPis的再次使用、初诊和复发性卵巢癌的二线或以上维持治疗,以及PARPis联合治疗等几个方面提出治疗建议,并提供推荐级别及证据强度。指南对于特定不良事件的管理也提出了建议,并就患者与临床医生的沟通方法和问题,以及研究的局限性和未来的研究方向进行了说明。

PARP inhibitors in the management of ovarian cancer: ASCO guideline

This article interpreted the recommendations of ASCO guideline on the use of poly (ADP-ribose) polymerase inhibitor (PARPi) for management of epithelial ovarian, tubal or primary peritoneal cancer. This systematic review-based guideline finally identified 17 eligible trials. Guideline recommendations were based on the review of evidence, US Food and Drug Administration approvals, and expert consensus when relevant evidence was lacking. The guideline pertains to patients who are PARPi na?ve. Treatment recommendations, evidence quality and strength of recommendations were provided on the aspects mainly focused on repeating PARPi, newly diagnosed ovarian cancer, second-line and beyond maintenance treatment of recurrent ovarian cancer as well as PARPi in combination therapy. The guideline also provided recommendations on the management of adverse events, and elaborated communications between patient and clinician, limitations of the research and future perspectives.